Current status and prospects of new radionuclides and radiopharmaceuticals for cardiovascular nuclear medicine

Journal Article · Wed Apr 01 04:00:00 EST 1987 · Semin. Nucl. Med.; (United States)

DOI:https://doi.org/10.1016/S0001-2998(87)80019-3· OSTI ID:6278929

Schelbert, H R

The rapid emergence of new imaging modalities like positron emission tomography (PET) and single photon emission computerized tomography (SPECT) and their advance into the clinical arena offered new opportunities for, but also stimulated research and development of new radiopharmaceuticals suitable for cardiac imaging. While tracers of myocardial blood flow remained in the center of interest, other trends heralded possibilities of studying more comprehensively cardiac physiology and pathophysiology as, for example, metabolism, the severity of tissue injury, neural activity and membrane function. N-13 ammonia and rubidium-82 became the primary tracers for evaluating and possibly quantifying regional myocardial blood flow with PET, while cationic Tc-99m isonitrile complexes have now reached a stage where high contrast images of the human heart are obtained on planar scintigraphy and SPECT. These radiopharmaceuticals hold considerable promise for routine clinical use. Tracers of metabolism, especially those labeled with positron emitting isotopes as for example, C-11 palmitate, F-18 2-deoxyglucose, are approaching the phase of clinical use and provide information on regional myocardial substrate metabolism and oxidative processes. Less successful and more limited were developments of single photon emitting tracers of metabolism which remained largely confined to radioiodinated fatty acid analogs. Exploration and characterization of the metabolic fate of the radiolabel in tissue and its relation to the externally observed signal have been truly impressive. Tested in humans primarily in western European countries, these tracers promise to yield metabolic information on a more limited scope. 211 references.

• OSTI ID: 6278929
• Journal Information: Semin. Nucl. Med.; (United States), Journal Name: Semin. Nucl. Med.; (United States) Vol. 2; ISSN SMNMA
• Country of Publication: United States
• Language: English

Related Subjects

550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
BODY
CARDIOVASCULAR DISEASES
CARDIOVASCULAR SYSTEM
COMPUTERIZED TOMOGRAPHY
DIAGNOSIS
DIAGNOSTIC TECHNIQUES
DISEASES
DRUGS
EMISSION COMPUTED TOMOGRAPHY
HEART
LABELLED COMPOUNDS
MEDICINE
MUSCLES
MYOCARDIUM
NUCLEAR MEDICINE
ORGANS
POSITRON COMPUTED TOMOGRAPHY
RADIOPHARMACEUTICALS
SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY
TOMOGRAPHY